JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan International Research Enhanced Equity ETF
JIRE
|
+$4.16B |
| 2 |
Microsoft
MSFT
|
+$2.29B |
| 3 |
Amazon
AMZN
|
+$2B |
| 4 |
UnitedHealth
UNH
|
+$1.76B |
| 5 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.42B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$4.61B |
| 2 |
Vanguard Short-Term Bond ETF
BSV
|
+$1.58B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$689M |
| 4 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$659M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.28% |
| 2 | Technology | 15.04% |
| 3 | Healthcare | 12.52% |
| 4 | Financials | 10.55% |
| 5 | Consumer Discretionary | 7.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2151
Primerica
PRI
$8.46B
| $9.14M | ﹤0.01% |
76,398
+9,440
| +14% | +$1.19M |
2013 Q2
36 quarters
|
|
|
KZR
2152
DELISTED
Kezar Life Sciences
KZR
| $9.11M | ﹤0.01% |
110,154
+103,775
| +1,627% | +$9.15M |
2018 Q3
15 quarters
|
|
2153
Red Rock Resorts
RRR
$2.89B
| $9.11M | ﹤0.01% |
272,920
-31,253
| -10% | -$1.25M |
2016 Q2
24 quarters
|
|
2154
SPS Commerce
SPSC
$3.03B
| $9.1M | ﹤0.01% |
80,520
-3,971
| -5% | -$449K |
2016 Q2
24 quarters
|
|
|
EGRX
2155
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $9.1M | ﹤0.01% |
204,847
-33,892
| -14% | -$1.56M |
2017 Q3
19 quarters
|
|
2156
iShares MSCI Chile ETF
ECH
$922M
| $9.09M | ﹤0.01% |
+377,563
| New | +$10.3M |
2022 Q2
0 quarters
|
|
|
JWN
2157
CALL
DELISTED
Nordstrom
JWN
| $9.09M | ﹤0.01% |
+430,000
| New | +$11M |
2022 Q2
0 quarters
|
|
2158
CALL
Marriott Vacations Worldwide
VAC
$3.55B
| $9.06M | ﹤0.01% |
+78,000
| New | +$11M |
2022 Q2
0 quarters
|
|
|
AEL
2159
DELISTED
American Equity Investment Life Holding Company
AEL
| $9.02M | ﹤0.01% |
246,622
-108,071
| -30% | -$4.11M |
2013 Q2
36 quarters
|
|
2160
Caesars Entertainment
CZR
$6.04B
| $9M | ﹤0.01% |
234,979
+39,669
| +20% | +$2.21M |
2017 Q3
19 quarters
|
|
2161
iShares MSCI Emerging Markets Asia ETF
EEMA
$893M
| $8.99M | ﹤0.01% |
132,010
-1,615
| -1% | -$112K |
2019 Q2
12 quarters
|
|
|
MRTX
2162
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.98M | ﹤0.01% |
133,800
+17,000
| +15% | +$1.08M |
2021 Q2
4 quarters
|
|
2163
State Street SPDR S&P Insurance ETF
KIE
$542M
| $8.97M | ﹤0.01% |
237,022
+164,378
| +226% | +$6.48M |
2017 Q2
20 quarters
|
|
|
SASR
2164
DELISTED
Sandy Spring Bancorp Inc
SASR
| $8.97M | ﹤0.01% |
229,600
+4,858
| +2% | +$199K |
2015 Q4
26 quarters
|
|
2165
CALL
Target
TGT
$71.2B
| $8.97M | ﹤0.01% |
63,500
+7,100
| +13% | +$1.36M |
2020 Q3
7 quarters
|
|
2166
PennyMac Financial
PFSI
$3.22B
| $8.96M | ﹤0.01% |
205,044
-121,221
| -37% | -$5.72M |
2014 Q3
31 quarters
|
|
2167
Hanmi Financial
HAFC
$925M
| $8.96M | ﹤0.01% |
399,073
+75,834
| +23% | +$1.76M |
2013 Q2
36 quarters
|
|
2168
Werner Enterprises
WERN
$2.06B
| $8.96M | ﹤0.01% |
232,396
-6,579
| -3% | -$259K |
2014 Q4
30 quarters
|
|
2169
iShares 5-10 Year Investment Grade Corporate Bond ETF
IGIB
$18.4B
| $8.93M | ﹤0.01% |
174,955
-9,625
| -5% | -$502K |
2013 Q2
36 quarters
|
|
2170
United Airlines
UAL
$36.3B
| $8.93M | ﹤0.01% |
252,144
-264,319
| -51% | -$11.6M |
2013 Q2
36 quarters
|
|
2171
iShares Intermediate Government/Credit Bond ETF
GVI
$3.73B
| $8.93M | ﹤0.01% |
84,593
+12,888
| +18% | +$1.37M |
2013 Q2
36 quarters
|
|
2172
Northwest Natural Holdings
NWN
$1.96B
| $8.92M | ﹤0.01% |
167,935
-66,952
| -29% | -$3.45M |
2013 Q2
36 quarters
|
|
2173
Utah Medical Products
UTMD
$236M
| $8.92M | ﹤0.01% |
103,814
+2,045
| +2% | +$174K |
2015 Q3
27 quarters
|
|
|
ISEE
2174
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $8.88M | ﹤0.01% |
923,597
+381,732
| +70% | +$4.79M |
2020 Q1
9 quarters
|
|
2175
PUT
Dominion Energy
D
$53.4B
| $8.88M | ﹤0.01% |
111,300
+70,800
| +175% | +$5.85M |
2021 Q1
5 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2022 Portfolio in Review
As of Q2 2022, JP Morgan Chase held 7,270 positions worth $718B, down 14% from $830B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q2 2022 filing shows 568 new, 2,561 increased, 2,728 reduced and 609 closed positions. Its largest new stake was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B. The largest sale was JPMorgan BetaBuilders Europe ETF, an estimated $4.61B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q2 2022 buy was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B.
- JP Morgan Chase added most to Microsoft in Q2 2022, an estimated $2.29B increase.
- JP Morgan Chase's biggest Q2 2022 reduction was JPMorgan BetaBuilders Europe ETF, cutting an estimated $4.61B.
- JP Morgan Chase fully exited Cerner Corp in Q2 2022, selling an estimated $608M.
- JP Morgan Chase's ten largest holdings make up 18% of its $718B portfolio in Q2 2022.
- JP Morgan Chase opened 568 new positions and closed 609 in Q2 2022.
- JP Morgan Chase's portfolio value fell 14% quarter-over-quarter to $718B.
Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.